Proteins manufacture

In an unwound heiix, the bases are exposed and can form new hydrogen-bonding interactions. In protein synthesis, the unwound DNA sequence serves as a tempiate to buiid a moiecuie of RNA whose base sequence is compiementary to that of the DNA sequence. The RNA moiecuie, in turn, serves as a biueprint for protein manufacture. In replication, as the iiiustration shows, unwinding and dupiication generates two identicai DNA heiices from a singie heiix. 

Plants are eukaryotic organisms whose post-translational functionalities empower protein synthesis capabilities, with the advantage of the economy of scale when cultivated at large scale. Therefore, the company s biomanufacturing is based in using plants as proteins manufacturers, since their capacity for folding proteins correctly at equivalent specific activities to those of native-sourced proteins. 

The development and commercial success of the first monoclonal antibody used to treat tumors in the United States have had broad consequences. Companies have pushed ahead with the development of a variety of additional monoclonal antibodies. Six years after rituximab was approved, more than one third of the 38 approved recombinant proteins manufactured in mammalian cells were antibodies (some of the most notable are listed in Table 32.1). Many of these antibodies are used at large doses that were not thought to be economically practical 10 years ago. Today, the pharmaceutical industry is facing a projected shortage of manufacturing plants for recombinant proteins synthesized by mammalian cells, and there are still more than 400 monoclonal antibodies reported to be in clinical trials. 

The extraction and purification of proteins from organisms or biological tissue can be a laborious and expensive process, and often represents the principal reason why vaccines and other therapeutic agents reach costs that become unattainable for many. Downstream processing also can be a major obstacle with respect to cost for large-scale protein manufacturing in plants. However, purification from plant tissues, while still costly, is in general less expensive than purification from their mammalian and bacterial counterparts. Indeed, some plant-derived biopharmaceuticals, such as topically applied monoclonal antibodies, may require only partial purification and thus be even less intensive in terms of labor and cost. 

Table 15.1 General process scheme for therapeutic protein manufacture.

Table 15.12 Comparison of small-molecules manufacture with therapeutic proteins manufacture with respect to usage of water and materials.

Ho, S.V., McLaughlin, J.M., Espen-schied, A.C., Kottmeier, R.E., and Bouressa, ).F. (2007) A preliminary green technology assessment of therapeutic protein manufacture. Presented at The Green Chemistry and Engineering Conference, June 29th, 2007 in Washington DC. 

Muller, L. L. 1982B. Milk proteins-manufacture and utilization. In Food Proteins. P. F. Fox and J. J. Condon (Editors). Applied Science Publishers, New York, pp. 179-189. 

Richert, S. H. 1975. Current milk protein manufacturing processes. J. Dairy Set 58, 985-993. 

Genentech, Inc., repotted the production of the first human protein manufactured in a bacteria somatostatin, a human growth hormone-releasing inhibitory factor. For the first time, a synthetic, recombinant gene was used to clone a protein. Many consider this to be the advent of the Age of Biotechnology. 

We have discussed both target receptors and pharmacokinetics in this book. Protein manufacture is under direct genetic control, and two factors are of particular relevance here. First, the precise structure and function of protein macromolecules (receptors) targeted by a specific drug molecule will vary in different individuals. Since the structure and function of the protein are directly related to how the drug molecule will interact with that protein, individuals responses to the drug will vary. Second, there are genetic variations in metabolic enzymes (proteins) and hence metabolism. Both of these processes fall neatly into the domain of pharmacoproteomics (see Section 14.8). 

Lastly, process synthesis is important in this field. The biologists dominate process synthesis in the recombinant DNA and protein manufacturing business. What limitations prevent chemical engineers from making contributions There are two an almost complete absence of predictive models based on fundamentals and a poor understanding of the physical and chemical properties of biological materials. These issues need to be addressed in both teaching and research. 

Over the past two decades, advances in peptide and protein manufacturing technologies have led to the production of many novel therapeutic agents (1). These new drug candidates are commonly administered by injection to avoid the complexities associated with either oral or pulmonary delivery. Proteolysis in the digestive tract is the primary obstacle to oral protein delivery, and reproducible delivery to the deep lung is the primary obstacle to pulmonary peptide... 

The strong hydrochloric acid, naturally present in the stomach, hydrolyses (adding on the elements of water) the foods containing proteins to form small amino acids for transport by the blood into cells. These small amino acid units are the starter building blocks for specific sequences of amino acids needed inside the cells for protein building. The proteins manufactured in the cells are different from those taken in as food, which is why they first have to be broken down into small units for eventual remaking and rearranging into those specifically required by the cells. 

A useful review of the considerations in multiuse protein manufacturing facility. 

Rlgra.stim aI.so promotes the production of neutrophil precursors in the bone marrow. This granulocyte colony-stimo lating factor (G-CSF) is a 17.5-amino acid protein manufactured by recombinant DNA technology. It is identical in sequence with the natural protein except for an N-termiitil methionine necessary for expression in . coti. It has no glycosylation because of its production in . cedi. 

---